Masimo (NASDAQ:MASI) updated its FY20 earnings guidance on Tuesday. The company provided earnings per share guidance of $3.56 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.58. The company issued revenue guidance of $1.035, compared to the consensus revenue estimate of $1.02 billion.Masimo also updated its FY 2019
Pre-Market guidance to 3.18 EPS.

Masimo stock traded down $2.83 during mid-day trading on Tuesday, reaching $162.17. The company’s stock had a trading volume of 3,902 shares, compared to its average volume of 302,750. The company has a market capitalization of $8.68 billion, a price-to-earnings ratio of 53.56, a price-to-earnings-growth ratio of 2.02 and a beta of 1.13. Masimo has a 12 month low of $110.98 and a 12 month high of $165.48. The business’s 50 day simple moving average is $157.78 and its 200 day simple moving average is $151.93.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $0.76 EPS for the quarter, topping the consensus estimate of $0.73 by $0.03. The firm had revenue of $229.01 million for the quarter, compared to analysts’ expectations of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.71 EPS. As a group, analysts predict that Masimo will post 3.17 earnings per share for the current fiscal year.

Several research analysts recently commented on the company. BidaskClub raised Masimo from a hold rating to a buy rating in a research report on Monday, December 16th. Piper Jaffray Companies restated an overweight rating and issued a $175.00 price target (up from $161.00) on shares of Masimo in a research note on Tuesday, December 17th. Finally, ValuEngine lowered Masimo from a buy rating to a hold rating in a research report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Masimo presently has an average rating of Buy and an average price target of $161.75.

In related news, EVP Thomas Samuel Mcclenahan sold 500 shares of the business’s stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $159.29, for a total transaction of $79,645.00. Following the transaction, the executive vice president now directly owns 5,607 shares of the company’s stock, valued at approximately $893,139.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Anand Sampath sold 15,000 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $155.00, for a total value of $2,325,000.00. Following the completion of the sale, the executive vice president now owns 27,518 shares in the company, valued at approximately $4,265,290. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,000 shares of company stock valued at $8,683,715. Corporate insiders own 11.50% of the company’s stock.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Story: Monthly Dividend Stocks

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.